http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107936118-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-08 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-107 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-65 |
| filingDate | 2017-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-107936118-B |
| titleOfInvention | Antibody-dolastatin conjugate as well as preparation method and application thereof |
| abstract | The invention discloses a preparation method of an antibody-dolastatin conjugate, which comprises the following steps: (1) providing a monoclonal antibody of an anti-MART-1 protein presentation peptide EAAGIGILTV/HLA-A2 complex with an LPXTG sequence at the C terminal, dolastatin with an oligoglycine linker or a dolastatin derivative; (2) under the catalysis of Sortase A enzyme, the LPXTG sequence and the oligoglycine linker generate transpeptidation reaction, so that the monoclonal antibody is coupled with the dolastatin or dolastatin derivative with the oligoglycine linker; (3) after the reaction is finished, separating and purifying to obtain the antibody-dolastatin conjugate. The invention leads each molecule of antibody to carry 4 molecules of MMAE toxin through site-specific coupling, has good uniformity and shows good tumor killing capability in vivo experiments; compared with the existing ADCs target point, the CLA 12-vcMAE ADCs expand the selection area of the current ADCs target point, and demonstrate the view that intracellular proteins can also be used as the ADCs drug target point through the presentation of MHC I molecules. |
| priorityDate | 2017-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 430.